Heartburn, inflammatory bowel diseases (IBD), inflammatory bowel syndrome (IBS), constipation, and diarrhea are among the common digestive problems. Gastrointestinal (GI) diseases account for substantial healthcare utilization and spending. The stomach is lined with a mucous membrane composed of cells and glands. The cells are prone to inflammation, leading to peptic ulcers, which may potentially develop into gastric cancer. Problems caused by stomach acid backflowing into the esophagus, known as gastroesophageal reflux disease (GERD), also increase the risk of developing gastric cancer. Despite declining incidence and mortality during the last decades, stomach cancer is perceived as one of the main health challenges. The prevalence of irritable bowel syndrome (IBS) has increased across the region in the last few decades. In contrast to a decline in the overall incidence of gastric cancer, it has surged among young adults in the last few decades. Thus, the increasing prevalence of gastrointestinal (GI) disease results in a high risk of developing gastric cancer, which drives the growth of the gastric cancer diagnostic procedures market.
The Europe gastric cancer diagnostic procedure market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant share of the global gastric cancer diagnostic procedure market. The market in Europe is expected to witness significant growth during the forecast period due to factors such as the high incidence of stomach cancer and Helicobacter pylori infection, growth in the geriatric population, and efforts made by various institutes to spread awareness of gastric cancer. Germany is one of the fastest-growing markets for gastric cancer diagnostic procedures in Europe. According to The Robert Koch Institute, H. pylori and Epstein-Barr virus infections are reported to be the major cause of stomach cancer. Germany reports a high incidence of H. pylori infection. According to a study published in Clinical Microbiology and Infection Journal (ELSEVIER) in 2020, H. pylori infected ~25% of the total population in Germany and caused gastritis that becomes more complicated with gastric adenocarcinoma.
The Europe gastric cancer diagnostic procedure market is segmented into healthcare provider, symptom type, body fluid, procedure, offering, disease indication, and country.
Based on healthcare provider, the Europe gastric cancer diagnostic procedure market is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, and others. The hospitals segment held the largest market share in 2022. In terms of body fluid, the Europe gastric cancer diagnostic procedure market is segmented into blood, urine, saliva, stomach wash/gastric juice, tissue, and others. The blood segment held the largest market share in 2022. The Europe gastric cancer diagnostic procedure market, by offering, is segmented into instruments, reagents & consumables, and services. The reagents & consumables segment held the largest market share in 2022.
Based on diagnostic procedure, the Europe gastric cancer diagnostic procedure market is categorized into endoscopic procedures, biopsy and tissue tests, lab tests, in-vitro diagnostic tests, imaging tests, molecular diagnostics, multiplexing molecular diagnostics, immunoassays, and others. The imaging segment held the largest share of the market in 2022. The Europe gastric cancer diagnostic procedure market, based on disease condition, is bifurcated into early gastric cancer and advanced type gastric cancer. The advanced type gastric cancer segment held a larger market share in 2022.
Based on country, the Europe gastric cancer diagnostic procedure market has been categorized into the UK, Germany, France, Italy, Spain, and Rest of Europe. Germany dominated the market in this region in 2022.
Agilent Technologies Inc, Atlas-Link Biotech Co Ltd, BioMerieux SA, Bio-Rad Laboratories Inc, F. Hoffmann-La Roche Ltd, Illumina Inc, Myraid Genetics Inc, Thermo Fisher Scientific Inc, and Vela Diagnostics Holding Pte Ltd. are the leading companies operating in the Europe gastric cancer diagnostic procedure market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 464.72 Million |
| Market Size by 2028 | US$ 674.76 Million |
| CAGR (2022 - 2028) | 6.4% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Healthcare Providers
|
|
Regions and Countries Covered
|
|
| Europe | UK, Germany, France, Russia, Italy, Rest of Europe |
| Market leaders and key company profiles |
|
The Europe Gastric Cancer Diagnostic Procedure Market is valued at US$ 464.72 Million in 2022, it is projected to reach US$ 674.76 Million by 2028.
As per our report Europe Gastric Cancer Diagnostic Procedure Market, the market size is valued at US$ 464.72 Million in 2022, projecting it to reach US$ 674.76 Million by 2028. This translates to a CAGR of approximately 6.4% during the forecast period.
The Europe Gastric Cancer Diagnostic Procedure Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Gastric Cancer Diagnostic Procedure Market report:
The Europe Gastric Cancer Diagnostic Procedure Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Gastric Cancer Diagnostic Procedure Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Gastric Cancer Diagnostic Procedure Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For Europe Gastric Cancer Diagnostic Procedure Market
